Foldikine™ Platform Pipeline

About Orikine Bio

Orikine Bio is a private, preclinical-stage biotech developing novel cytokine therapeutics using its proprietary Foldikine™ platform. The platform engineers bi-specific cytokines to deliver precise signals to specific cells, aiming to correct immune dysfunction in autoimmune and inflammatory diseases with a high therapeutic index. Founded in 2021/2022, the company has raised €5.5M in seed funding from investors like Asabys and AdBio and has secured significant non-dilutive grant funding. Orikine Bio represents a convergence of computational protein design and immunology, seeking to address a major unmet need in autoimmunity with a potentially safer, more effective modality.

Therapeutic Areas

Other Autoimmune and Inflammatory Diseases Drugs